Rediscovery of thalidomide. Successful treatment of discoid lupus erythematosus;Wiederentdeckung von thalidomid: Erfolgreiche behandlung des chronisch diskoiden lupus erythematodes

Hautarzt

Volumn 52, Issue 8, 2001, Pages 726-733

  Kuhn, A ^a   Hefter, H ^a   Ruzicka, T ^a   Lehmann, P ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Klinikum Wuppertal   (Germany)

Author keywords

Autoimmune diseases; Discoid lupus erythematosus; Polyneuropathy; Refractory treatment; Thalidomide

Indexed keywords

THALIDOMIDE;

ADULT; ANAMNESIS; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; DISCOID LUPUS ERYTHEMATOSUS; DRUG WITHDRAWAL; GERMANY; HUMAN; POLYNEUROPATHY; TERATOGENICITY; TREATMENT OUTCOME;

ADULT; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, DISCOID; MALE; MIDDLE AGED; THALIDOMIDE; TIME FACTORS;

EID: 0034885625     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050170091     Document Type: Article

References (68)

1. Thalidomide-induced peripheral neuropathy
2. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide
3. Lupus eritematoso discoide y talidomina
4. Studies on the inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes
5. Cellular immune effects of thalidomide in actinic prurigo
6. Thalidomide for systemic lupus erythematosus
7. Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide
8. Management of antimalarial-refractory cutaneous lupus erythematosus
9. Thalidomide neurotoxicity
10. Thalidomide revisited
11. A quantitative ultrastructural study of motor and sensory lumbosacral nerve roots in the thalidomid-treated rabbit fetus
12. Guidelines of care for cutaneous lupus erythematosus
13. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus
14. Inhibition of PMN leukocytes chemotaxis by thalidomide
15. Thalidomide neuropathy: A clinical, electrophysiological, and histological follow-up study
16. Thalidomide induces imbalances in T-lymphocytes subpopulations in the circulating blood of healthy males
17. Thalidomide treatment for hypertrophic lupus erythematosus
18. Thalidomide: Treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus
19. Thalidomide therapy for inflammatory dermatoses
20. Thalidomide in human immunodeficiency virus (HIV) patients: A review of safety considerations
21. Thalidomide in the treatment of chronic discoid lupus erythematosus
22. Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients
23. Thalidomide-induced peripheral neuropathy: A prospective clinical, neurophysiological and pharmacogenetic evaluation
24. Chronic cutaneous lupus erythematosus treated with thalidomide
25. Thalidomid in der dermatologie
26. Immunosuppressive properties of thalidomide
27. Treatment of chronic lupus erythematosus with thalidomide
28. Treatment of lupus erythematosus profundus with thalidomide
29. Thalidomidbehandlung des chronisch diskoiden lupus erythematodes
30. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus
31. Cutaneous manifestations of lupus erythematosus. What is important for rheumatologists?
32. Thalidomide neuropathy: An electrophysiologic study
33. Treatment of discoid lupus erythematosus
34. Elektrophysiologische veränderungen bei thalidomid-neuropathie unter behandlung des lupus erythematodes discoides
35. Thalidomide inhibits the replication of human immunodeficiency virus type 1
36. The immunosuppressive drug thalidomide induces T-helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
37. The saga of thalidomide: Neuropathy to embryopathy, with case reports and congenital abnormalities
38. The saga of thalidomide (concluded)
39. Treatment of porphyria cutanea tarda with oral thalidomide
40. Thalidomide treatment of subacute cutaneous lupus erythematosus
41. Thalidomide therapy: An open trial
42. Thalidomide and the immune system: Down regulation of the CD 26 receptor, probably involved in the binding of HIV components to T cells in primates
43. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients
44. Thalidomide induces amenorrhea in patients with lupus disease
45. Pustuloderma during cutaneous lupus treatment with thalidomide
46. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
47. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
48. La thalidomide dans le traitement du lupus érythémateux chronique (L.E.C.)
49. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus
50. Polymorphous light eruption: Treatment with thalidomide
51. La thalidomide dans le traitement du lupus érythémateux chronique
52. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy
53. Thalidomide in the treatment of lepra reactions
54. Therapeutische erfahrungen über den einfluβ des thalidomids bei der leprareaktion
55. The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide
56. Lupus erythematosus
57. Proposed mechanisms of action in thalidomide embryopathy
58. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients
59. Thalidomide and its impact in Dermatology
60. Therapie des Lupus erythematodes 1994
61. Heutige Aspekte beim kutanen Lupus erythematodes
62. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
63. Binding of thalidomide to alpha 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production
64. Thalidomide for the treatment of chronic graft-versus-host disease
65. Behandlung eines subakut kutanen lupus erythematodes mit thalidomid
66. Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus
67. Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus
68. Development of polyneuropathy during thalidomide therapy